Literature DB >> 15222974

An Anacardiaceae preparation reduces the expression of inflammation-related genes in murine macrophages.

J Leiro1, D García, J A Arranz, R Delgado, M L Sanmartín, F Orallo.   

Abstract

This study investigated the effects of an aqueous extract of the stem bark of Mangifera indica L. (Anacardiaceae; Vimang), which contains a defined mixture of components including polyphenols (principally mangiferin, MA), triterpenes, phytosteroids, fatty acids and microelements, on expression of inflammation mediators in inflammatory murine macrophages after stimulation in vitro with lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma). In vitro treatment with Vimang at 4 microg/ml reduced levels of NOS-2 mRNA and NOS-2, while treatment at 40 microg/ml also reduced levels of COX-2 mRNA, COX-2, and prostaglandin E2 (PGE2). Results suggested that MA is involved in these effects. In vitro treatment with Vimang at 40 microg/ml also inhibited mRNA levels of the proinflammatory cytokines interleukin 1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha) and colony-stimulating factor (GM-CSF), but did not affect mRNA levels of IL-6 or tumor growth factor-beta (TGF-beta). Extracellular release of TNF-alpha by inflammatory macrophages was inhibited by in vitro treatment with Vimang at the same concentrations that showed inhibition of TNF-alpha mRNA levels. The inhibition of TNF-alpha production appears to be at least partially attributable to MA. Vimang at 4 microg/ml decreased mRNA levels of nuclear factor-kappaB (NF-kappaB) but did not affect expression of the NF-kappaB inhibitor (IkappaB). These data indicate that the potent anti-inflammatory effects of Vimang are due to selective modulation of the expression of inflammation-related genes, leading to attenuation of macrophage activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222974     DOI: 10.1016/j.intimp.2004.02.003

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  Mangiferin decreases inflammation and oxidative damage in rat brain after stress.

Authors:  Lucía Márquez; Borja García-Bueno; José L M Madrigal; Juan C Leza
Journal:  Eur J Nutr       Date:  2011-10-07       Impact factor: 5.614

Review 2.  The globalization of traditional medicine in northern peru: from shamanism to molecules.

Authors:  Rainer W Bussmann
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-28       Impact factor: 2.629

3.  Anti-inflammatory effects of Mangifera indica L. extract in a model of colitis.

Authors:  Lucía Márquez; Beatriz G Pérez-Nievas; Icíar Gárate; Borja García-Bueno; José Lm Madrigal; Luis Menchén; Gabino Garrido; Juan C Leza
Journal:  World J Gastroenterol       Date:  2010-10-21       Impact factor: 5.742

4.  Effects of a Mangifera indica L. stem bark extract and mangiferin on radiation-induced DNA damage in human lymphocytes and lymphoblastoid cells.

Authors:  I Rodeiro; R Delgado; G Garrido
Journal:  Cell Prolif       Date:  2013-11-22       Impact factor: 6.831

5.  Mangiferin attenuates TH1/TH2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model.

Authors:  Hong-Wei Guo; Chen-Xia Yun; Guang-Han Hou; Jun Du; Xin Huang; Yi Lu; Evan T Keller; Jian Zhang; Jia-Gang Deng
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

6.  Mangiferin induces cell death against rhabdomyosarcoma through sustained oxidative stress.

Authors:  Vishwanadha Vijaya Padma; Palanisamy Kalaiselvi; Rangasamy Yuvaraj; M Rabeeth
Journal:  Integr Med Res       Date:  2014-10-02

Review 7.  A Mangifera indica L. extract could be used to treat neuropathic pain and implication of mangiferin.

Authors:  Bárbara B Garrido-Suárez; Gabino Garrido; Rene Delgado; Fe Bosch; María del C Rabí
Journal:  Molecules       Date:  2010-12-09       Impact factor: 4.411

Review 8.  A Review on Ethnopharmacological Applications, Pharmacological Activities, and Bioactive Compounds of Mangifera indica (Mango).

Authors:  Meran Keshawa Ediriweera; Kamani Hemamala Tennekoon; Sameera Ranganath Samarakoon
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-31       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.